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Abstract 
Background: Aortic valve stenosis (AVS) and coronary artery disease (CAD) have a 
significant genetic contribution and commonly co-exist. To compare and contrast genetic 
determinants of the two diseases, we investigated associations of the LPA and 9p21 loci, i.e. 
the two strongest CAD risk loci, with risk of AVS.  
Methods: We genotyped the CAD-associated variants at the LPA (rs10455872) and 9p21 loci 
(rs1333049) in the GeneCAST (Genetics of Calcific Aortic STenosis) Consortium and 
conducted a meta-analysis for their association with AVS. Cases and controls were stratified 
by CAD status. External validation of findings was undertaken in five cohorts including 7,880 
cases and 851,152 controls.  
Results: In the meta-analysis including 4,651 cases and 8,231 controls the CAD-associated 
allele at the LPA locus was associated with increased risk of AVS (OR 1.37; 95%CI 1.24-1.52, 
p=6.9x10-10) with a larger effect size in those without CAD (OR 1.53; 95%CI 1.31-1.79) 
compared to those with CAD (OR 1.27; 95%CI 1.12-1.45). The CAD-associated allele at 9p21 
was associated with a trend towards lower risk of AVS (OR 0.93; 95%CI 0.88-0.99, p=0.014). 
External validation confirmed the association of the LPA risk allele with risk of AVS (OR 1.37; 
95%CI 1.27-1.47), again with a higher effect size in those without CAD. The small protective 
effect of the 9p21 CAD risk allele could not be replicated (OR 0.98; 95%CI 0.95-1.02). 
Conclusions: Our study confirms the association of the LPA locus with risk of AVS, with a 
higher effect in those without concomitant CAD. Overall, 9p21 was not associated with AVS.  
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Introduction 
Progressive calcification of the aortic valve leaflets leads to a high prevalence of aortic valve 
stenosis (AVS) in the elderly population (>75 years) resulting in the most common form of 
degenerative valvular heart disease { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. The 
long-time course before it becomes severe enough to cause symptoms and affect prognosis 
provides a significant opportunity to prevent its progression. As soon as patients become 
symptomatic, mortality increases up to 50% within two years { ADDIN EN.CITE 
<EndNote><Cite><Author>Otto</Author><Year>2014</Year><RecNum>146</RecNum><
DisplayText>[2]</DisplayText><record><rec-number>146</rec-number><foreign-
keys><key app="EN" db-id="rppdfdx57tvp2lezwacv2s5rawafxdfe52w0" 
timestamp="1511955659">146</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Otto, C. 
M.</author><author>Prendergast, B.</author></authors></contributors><auth-address>From 
the Division of Cardiology, Department of Medicine, University of Washington School of 
Medicine, Seattle (C.M.O.); and the Department of Cardiology, John Radcliffe Hospital, 
Oxford, United Kingdom (B.P.).</auth-address><titles><title>Aortic-valve stenosis--from 
patients at risk to severe valve obstruction</title><secondary-title>N Engl J Med</secondary-
title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>744-
56</pages><volume>371</volume><number>8</number><edition>2014/08/21</edition><k
eywords><keyword>*Aortic Valve 
Stenosis/classification/physiopathology/surgery</keyword><keyword>Disease 
Progression</keyword><keyword>*Heart Valve Prosthesis 
Implantation</keyword><keyword>Humans</keyword><keyword>Risk 
Factors</keyword><keyword>Ventricular Function, 
Left</keyword></keywords><dates><year>2014</year><pub-dates><date>Aug 
21</date></pub-dates></dates><isbn>1533-4406 (Electronic)&#xD;0028-4793 
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(Linking)</isbn><accession-num>25140960</accession-num><urls><related-
urls><url>https://www.ncbi.nlm.nih.gov/pubmed/25140960</url></related-
urls></urls><electronic-resource-num>10.1056/NEJMra1313875</electronic-resource-
num></record></Cite></EndNote>} and surgical or percutaneous aortic valve replacement 
remain the only current therapeutic options { ADDIN EN.CITE 
<EndNote><Cite><Author>Baumgartner</Author><Year>2017</Year><RecNum>177</Re
cNum><DisplayText>[3]</DisplayText><record><rec-number>177</rec-number><foreign-
keys><key app="EN" db-id="rppdfdx57tvp2lezwacv2s5rawafxdfe52w0" 
timestamp="1517478292">177</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Baumgartner, 
H.</author><author>Falk, V.</author><author>Bax, J. J.</author><author>De Bonis, 
M.</author><author>Hamm, C.</author><author>Holm, P. J.</author><author>Iung, 
B.</author><author>Lancellotti, P.</author><author>Lansac, E.</author><author>Rodriguez 
Munoz, D.</author><author>Rosenhek, R.</author><author>Sjogren, 
J.</author><author>Tornos Mas, P.</author><author>Vahanian, 
A.</author><author>Walther, T.</author><author>Wendler, 
O.</author><author>Windecker, S.</author><author>Zamorano, J. L.</author><author>E. S. 
C. Scientific Document Group</author></authors></contributors><titles><title>2017 
ESC/EACTS Guidelines for the management of valvular heart disease</title><secondary-
title>Eur Heart J</secondary-title></titles><periodical><full-title>Eur Heart J</full-
title></periodical><pages>2739-
2791</pages><volume>38</volume><number>36</number><edition>2017/09/10</edition>
<keywords><keyword>Aortic regurgitation</keyword><keyword>Aortic 
stenosis</keyword><keyword>Guidelines</keyword><keyword>Mitral 
regurgitation</keyword><keyword>Mitral stenosis</keyword><keyword>Percutaneous valve 
intervention</keyword><keyword>Prosthetic heart valves</keyword><keyword>Tricuspid 
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regurgitation</keyword><keyword>Tricuspid stenosis</keyword><keyword>Valve 
disease</keyword><keyword>Valve 
surgery</keyword></keywords><dates><year>2017</year><pub-dates><date>Sep 
21</date></pub-dates></dates><isbn>1522-9645 (Electronic)&#xD;0195-668X 
(Linking)</isbn><accession-num>28886619</accession-num><urls><related-
urls><url>https://www.ncbi.nlm.nih.gov/pubmed/28886619</url></related-
urls></urls><electronic-resource-num>10.1093/eurheartj/ehx391</electronic-resource-
num></record></Cite></EndNote>}. With an increasingly ageing population in many 
countries, the need for other treatment options for AVS is gaining an ever-greater imperative. 
Development and progression of AVS is a multifactorial process involving several risk factors, 
e.g., smoking, high blood pressure, diabetes, and cholesterol. In addition, elevated levels of 
lipoprotein (a) (Lp(a)) { ADDIN EN.CITE { ADDIN EN.CITE.DATA }} and predisposition 
for high LDL-cholesterol are associated with AVS { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. Thus, development of AVS represents an active process involving lipid 
metabolism and inflammation { ADDIN EN.CITE { ADDIN EN.CITE.DATA }} – largely 
replicating the risk factors underlying coronary artery disease (CAD). However, despite 
identification of risk factors and understanding of some of the biology of AVS { ADDIN 
EN.CITE 
<EndNote><Cite><Author>Iung</Author><Year>2011</Year><RecNum>98</RecNum><
DisplayText>[7]</DisplayText><record><rec-number>98</rec-number><foreign-keys><key 
app="EN" db-id="rppdfdx57tvp2lezwacv2s5rawafxdfe52w0" 
timestamp="1505305300">98</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Iung, 
B.</author><author>Vahanian, A.</author></authors></contributors><auth-
address>Cardiology Department, Bichat Hospital, AP-HP, Paris, France. 
bernard.iung@bch.aphp.fr</auth-address><titles><title>Epidemiology of valvular heart 
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disease in the adult</title><secondary-title>Nat Rev Cardiol</secondary-
title></titles><periodical><full-title>Nat Rev Cardiol</full-title></periodical><pages>162-
72</pages><volume>8</volume><number>3</number><keywords><keyword>Adult</key
word><keyword>Age Factors</keyword><keyword>Aortic Valve/*diagnostic 
imaging/pathology</keyword><keyword>Aortic Valve Stenosis/diagnostic 
imaging/epidemiology/pathology</keyword><keyword>Disease 
Progression</keyword><keyword>France/epidemiology</keyword><keyword>Global 
Health</keyword><keyword>Heart Valve Diseases/*diagnostic 
imaging/epidemiology/pathology</keyword><keyword>Humans</keyword><keyword>Mitr
al Valve/*diagnostic imaging/pathology</keyword><keyword>Mitral Valve 
Insufficiency/diagnostic imaging/epidemiology/pathology</keyword><keyword>Natriuretic 
Peptide, 
Brain/blood</keyword><keyword>Ultrasonography</keyword></keywords><dates><year>2
011</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>1759-5010 
(Electronic)&#xD;1759-5002 (Linking)</isbn><accession-num>21263455</accession-
num><urls><related-
urls><url>https://www.ncbi.nlm.nih.gov/pubmed/21263455</url></related-
urls></urls><electronic-resource-num>10.1038/nrcardio.2010.202</electronic-resource-
num></record></Cite></EndNote>} there has been little progress in development of 
preventative treatments.  
The first genome-wide association study (GWAS) of aortic valve disease focused on 
calcification of the aortic valve using computed tomography (CT) scan analysis and identified 
one SNP at the LPA locus (rs10455872) on chromosome 6 reaching genome-wide significance 
{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Aortic valve calcification correlates with 
the progression of AVS { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}, and subsequent 
studies have confirmed the association of the locus with AVS { ADDIN EN.CITE { ADDIN 
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EN.CITE.DATA }}. Recently, a GWAS of AVS identified two new loci on chromosome 1p21 
and 2q22, the first of these (PALMD) also associates with bicuspid aortic valve disease and 
aortic root size, whereas the second variant (TEX41) also associates with coronary artery 
disease { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. AVS and CAD are both age-related 
conditions, share several traditional risk factors and commonly co-exist { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}. Therefore, any analysis of genetic determinants of AVS needs to 
take into account the presence of CAD, and exclude the possibility that the association is a 
confounded association due to the presence of CAD. The aim of our study was to investigate 
the association of the LPA locus with hemodynamically significant AVS taking CAD into 
account and also to investigate whether the strongest non-lipid locus for CAD (9p21) shows an 
association with AVS.  
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Methods 
Discovery study population 
The discovery study consisted of three cohorts (Dundee, Leicester and Munich) from the 
Genetics of Calcific Aortic STenosis (GeneCAST) Consortium and the study flow chart is 
illustrated in the Supplementary Figure 1. All studies were approved by the respective 
institutional Ethics Committees and all patients consented to participate in the studies. All 
recruitments and analyses were performed in accordance with the Declaration of Helsinki.  
In all three cohorts from the GeneCAST consortium AVS was defined by standard 2D 
echocardiography as thickening of the aortic valve leaflets and evidence of at least mild aortic 
stenosis with an increased peak velocity >2.5 m/s. In addition, patients with aortic valve 
replacement for severe AVS were included.  
In GeneCAST Dundee patients were identified from the Genetics of Diabetes and Audit 
Research Tayside Study (GoDARTS) which has been described previously { ADDIN EN.CITE 
{ ADDIN EN.CITE.DATA }}. Briefly, a unique patient identifier to link demographic, 
echocardiographic, outcome and genotype databases was used. Patients with bicuspid aortic 
valves were excluded. Patients were categorized into CAD positive (+) or CAD negative (-). 
CAD+ was classified if they had a previous hospital admission due to CAD (primary or 
secondary diagnosis) as recorded by the Scottish Morbidity Record or their primary cause of 
death was due to CAD as recorded in the Scottish General Register Office of Births and Deaths 
based on the ICD-10 code. 
In GeneCAST Leicester cases and controls were classified into CAD+ and CAD- groups 
depending on their reported medical history. Patients with congenital aortic valve abnormalities 
including bicuspid aortic valves, evidence of rheumatic heart disease including moderate or 
severe mitral stenosis or mitral valve repair/replacement, aortic valve endocarditis, or aortic 
valve replacement before the age of 50 years were excluded from the analysis.  
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In GeneCAST Munich all patients (cases and controls) had undergone coronary angiography. 
If narrowing of the coronary arteries was <25% patients were classified as CAD-. Exclusion 
criteria were identical to the criteria from the GeneCAST Leicester cohort as stated above.  
 
External replication study populations 
External validation was performed using data from five additional cohorts, deCODE, 
ASAP/DAVAACA, HUNT, Malmo Diet and Cancer Study and the UK Biobank. Details on 
the study cohorts have been described in detail previously { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. In brief, the definition of AVS in deCODE was based on ICD-codes (I35.0, 
I35.2 for discharge diagnosis or the NOMESCO classification of surgical procedures codes 
(FMA, FMSA, FMD/FMSD and subcodes). The definition of CAD was taken from the 
deCODE genotype phenotype database { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. In 
the data from Karolinska Institute ASAP Biobank and its subsequently collected DAVAACA 
Biobank CAD was defined as significant stenosis on coronary angiogram. For the ASAP part 
of the Biobanks, individuals with CAD were excluded from the Biobank, explaining the general 
low level of CAD+ subjects in the Karolinska Institute analysis. The AVS status was assessed 
from transthoracic echocardiography. In UK Biobank AVS cases were defined as subjects with 
a self-reported history of AVS, or hospitalization or death due to ICD9 424.1 or ICD10 I35.0. 
CAD cases in UK Biobank were defined as a subject with self-reported history of heart 
attack/myocardial infarction, percutaneous transluminal coronary angioplasty, stent 
implantation, coronary artery bypass graft; or hospitalization for ICD9 410-412, ICD10 I21-
I24, I25.2, OPCS-4 K40-K46, K49, K50.1, K75, or the following cause of death (ICD10 I21-
I24, I25.2). In the HUNT study AVS was defined as ICD-10 code I35.0 or I35.2 and CAD was 
defined as individuals with self-reported coronary artery bypass graft, coronary angioplasty, or 
stent placement, or those with ICD-10 codes I21 or I25.2 or ICD-9 codes 410 or 412. In the 
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Malmo Diet and Cancer Study cases of AVS were retrieved from nationwide hospital registers 
{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} defined as ICD-9 424.1, ICD-10 I35.0 or 
I35.2. The definition of CAD was defined as a previous hospital diagnosis of myocardial 
infarction (ICD-9 410, ICD-10 I21), or if participants had undergone percutaneous coronary 
intervention or coronary artery bypass surgery.   
 
Genotyping  
In the GeneCAST Dundee cohort, samples were genotyped at the Affymetrix service laboratory 
on the Genome-Wide Human SNP Array 6.0. Genotype QC was via the standard protocol 
established for the Wellcome Trust Case Control Consortium 2 Study, as previously described 
{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. In the GeneCAST Leicester cohort SNP 
genotyping was performed using the Fluidigm EP1™ system at Source BioScience genomics 
services (Nottingham, UK). SNP genotyping in the GeneCAST Munich cohort was performed 
with TaqMan® Gene Expression Master Mix and TaqMan® MGB Probes VIC and FAM 
(ThermoFisher, Life Technologies, Carlsbad, USA) for allele labelling on a ViiA7 qPCR 
instrument (ThermoFisher, Life Technologies, Carlsbad, USA). The primers used for LPA 
(rs10455872) and 9p21 (rs1333049) genotyping are provided in the Supplementary Appendix. 
In UKB, participants were genotyped in two phases with the first 50,000 using the BiLEVE 
array and the remainder using the main UK Biobank array { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. In the Malmo Diet and Cancer study genotyping was performed using the 
Illumina Human Omni Express Exome BeadChip kit. In the Karolinska Institute analysis, the 
Illumina Human610-Quad BeadChip and Infinium Global Screening Arrays were used (416 
and 922 individuals respectively). In the deCODE study genotyping was performed either using 
Illumina SNP chips or data was taken from whole genome sequencing. The HUNT study 
performed genotyping using the IlluminaCoreExome array.  
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Lp(a) Measurements 
In a subgroup of AVS cases without CAD from the GeneCAST Munich cohort, plasma levels 
of Lp(a) were measured. As previously described { ADDIN EN.CITE 
<EndNote><Cite><Author>Levine</Author><Year>1992</Year><RecNum>60</RecNum>
<DisplayText>[20]</DisplayText><record><rec-number>60</rec-number><foreign-
keys><key app="EN" db-id="rppdfdx57tvp2lezwacv2s5rawafxdfe52w0" 
timestamp="1500461040">60</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Levine, D. 
M.</author><author>Sloan, B. J.</author><author>Donner, J. E.</author><author>Lorenz, J. 
D.</author><author>Heinzerling, R. H.</author></authors></contributors><auth-
address>Rogosin Institute, New York Hospital, Cornell Medical Center, NY 10021.</auth-
address><titles><title>Automated measurement of lipoprotein(a) by immunoturbidimetric 
analysis</title><secondary-title>Int J Clin Lab Res</secondary-
title></titles><periodical><full-title>Int J Clin Lab Res</full-title></periodical><pages>173-
8</pages><volume>22</volume><number>3</number><keywords><keyword>Antibody 
Formation/immunology</keyword><keyword>Antigens/biosynthesis</keyword><keyword>
Automation</keyword><keyword>Enzyme-Linked Immunosorbent 
Assay</keyword><keyword>Humans</keyword><keyword>Lipoprotein(a)</keyword><key
word>Lipoproteins/*analysis</keyword><keyword>Male</keyword><keyword>Nephelomet
ry and 
Turbidimetry</keyword><keyword>Phenotype</keyword></keywords><dates><year>1992
</year></dates><isbn>0940-5437 (Print)&#xD;0940-5437 (Linking)</isbn><accession-
num>1387818</accession-num><urls><related-
urls><url>https://www.ncbi.nlm.nih.gov/pubmed/1387818</url></related-
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urls></urls></record></Cite></EndNote>}, Lp(a) mass was analysed using an 
immunoturbimetry method and measurements were performed on an automated analyser 
(Cobas MIRA, Roche, Basel Switzerland). In addition, we retrospectively analysed the 
routinely assessed Lp(a) levels of patients undergoing transcatheter aortic valve replacement 
(TAVR) for severe aortic stenosis at the German Heart Center Munich, Munich, Germany 
between September 2016 and September 2018. Definition of CAD in these patients was based 
on coronary angiography prior to TAVR procedure.  
 
Statistical analysis 
Analyses of association of the two variants with AVS were performed using logistic regression 
in unadjusted models within each GeneCAST cohort stratified by CAD status. Results were 
combined using a fixed-effect inverse-variance weighted meta-analysis on the log-odds ratios, 
with consideration of study heterogeneity using the I2 statistic. In the external validation in 
UKB, due to the level of relatedness within UK Biobank, a family identifier was derived based 
on kinship scores, where any individuals found to be related (k>0.044) were joined into a 
family. All validation cohorts performed logistic regression analyses adjusting for age, sex, , 
the first five principal components statin use, array type in UKB (BiLEVE array versus main 
UK Biobank array) with family fitted as a random effect where required using mixed models. 
Lp(a) plasma levels were compared using unpaired Student t test. Analysis of Lp(a) quartiles 
was performed using one-way ANOVA and post trend analysis. Comparisons of allele 
frequencies were performed using two sample test of proportions. All analyses were conducted 
using Stata version 13.1.  
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Results 
The baseline characteristics of the discovery study cohorts are summarised in the 
Supplementary Table 1. The cases in all cohorts are typical of clinical patients with 
degenerative AVS.  
 
Association of the LPA locus with AVS 
CAD risk allele (G) frequencies for rs10455872 for each cohort and association analysis of the 
LPA CAD risk allele with risk of AVS in each cohort are shown in Figure 1 and Table 1. 
Results were consistent across all three cohorts and the meta-analysis confirmed a strongly 
significant association of the LPA locus with risk of AVS (Odds ratio (OR) 1.37; 95% 
confidence interval (CI) 1.24-1.52, p=6.9x10-10) (Figure 1). Interestingly, the effect size for the 
LPA risk allele was lower in the cohorts with CAD (meta OR 1.27; 95% CI 1.12-1.45, p=2.8x10-
4) compared to the cohorts without CAD (meta OR 1.53; 95% CI 1.31-1.79, p=1.2x10-7), 
although a test for interaction was not statistically significant.  
 
Association of the 9p21 locus with AVS 
CAD risk allele (C) frequencies for rs1333049 for each cohort are shown in Figure 1 and Table 
1. At the individual cohort level, there was no association of the CAD risk allele with risk of 
AVS. In the overall meta-analysis, the 9p21 CAD risk allele showed a trend towards a lower 
risk of AVS (OR 0.93; 95% CI 0.88-0.99, p=0.014). When stratified by CAD status, there was 
a small protective effect of the 9p21 CAD risk allele with lower risk of AVS in the cohorts with 
CAD (meta OR 0.91; 95% CI 0.85-0.99, p= 0.019), but not in the cohorts without CAD (meta 
OR 0.96; 95% CI 0.88-1.04, p=0.278) (Figure 1).  
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External validation  
External validation in 7,880 cases and 851,192 controls for the association analysis of the LPA 
risk allele in five additional cohorts showed similar effect estimates with an overall OR of 1.37 
(95% CI 1.27-1.47) (Figure 2 and Supplementary Table 2). Likewise, the ORs showed a 
higher effect size for the LPA risk allele in subjects without CAD compared to those with CAD 
OR 1.46 (95% CI 1.31-1.62) and OR 1.29 (95% CI 1.17-1.43), respectively. Analysis of the 
9p21 CAD risk allele in the replication studies did not confirm an association with lower risk 
of AVS with an overall OR of 0.98 (95% CI 0.95-1.02) (Figure 2 and Supplementary Table 
2).  
 
Exploration for survival bias 
Given the well-validated relationship between the 9p21 locus and CAD risk, one possibility for 
the finding of a potential inverse association of the CAD risk allele with AVS risk could be that 
a greater proportion of subjects carrying this allele develop CAD and die before they can 
develop AVS and thus impact on the association of the genotype with AVS. Similarly, the 
slightly reduced association of the LPA locus with AVS in the CAD+ group compared with the 
CAD- group could similarly represent a possible relative loss of the LPA risk allele in the CAD+ 
due to premature CAD death in carriers. To investigate these possibilities, we analysed risk 
allele frequencies by CAD status within AVS groups in GeneCAST, combined across all the 
cohorts. As shown in the Supplementary Figure 2, although the risk allele frequencies in those 
with AVS were higher for LPA and lower for 9p21 as might be expected from the observed 
associations with AVS, the association with CAD was observed in all four groups irrespective 
of AVS status without significant difference in the proportionate relationship (Supplementary 
Figure 2). This would argue against a substantial survival effect impacting on the findings.  
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Association of the LPA locus with circulating Lipoprotein (a) levels 
To investigate whether LPA genotype was also associated with circulating lipoprotein (a) 
(Lp(a)) levels, we analysed a subgroup of 278 individuals with AVS from the GeneCAST 
Munich CAD- cohort with both available LPA genotype and Lp(a) plasma levels. Lp(a) levels 
were only available from heterozygous individuals (AG, n=41) and homozygous non-risk allele 
carriers (AA, n=237). The risk allele (G) was associated with significantly higher circulating 
Lp(a) levels (AG vs. AA: 88.22 ± 7.0 mg/dl vs. 23.96 ± 7.1 mg/dl; p<0.001).  
 
Lipoprotein (a) levels and age at TAVR symptomatic severe AVS 
To analyse whether the observed difference in risk of AVS between patients with CAD and 
patients without CAD depends on Lp(a) plasma levels we analysed Lp(a) levels in patients with 
symptomatic severe AVS undergoing TAVR. After classification of 451 patients into quartiles 
by their Lp(a) level there was a linear decrease in the mean age at TAVR (from 80.1 years to 
75.8 years, p for linear trend 0.01) but only in those without CAD (Figure 3). In patients with 
CAD, the mean age at TAVR only slightly differed between those with high and those with low 
Lp(a) level quartiles (from 79.6 years to 78.2 years, p for the trend 0.09).  
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Discussion 
In our analysis we confirmed a robust association of AVS with the LPA locus, independent of 
concomitant CAD, which was replicated in five external cohorts. Interestingly, the effect size 
of the LPA risk allele was higher in patients without concomitant CAD. Similar, patients 
without CAD and high Lp(a) levels developed symptomatic severe AVS earlier. In addition, 
we identified a potential protective effect of the CAD risk allele at 9p21. However, this finding 
did not replicate in the validation cohorts.  
In 2013 Thanassoulis and colleagues { ADDIN EN.CITE { ADDIN EN.CITE.DATA }} 
reported an association of aortic valve calcification with the LPA locus, specifically with 
rs10455872 { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Since then several subsequent 
cross-sectional and prospective studies have confirmed the association of this variant with AVS 
{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. The risk (G) allele at rs10455872 is 
associated with increased plasma Lp(a) levels { ADDIN EN.CITE { ADDIN EN.CITE.DATA 
}}, as we also show here. Higher Lp(a) levels are also associated with risk of AVS{ ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }} providing a mechanism by which genetic variation at 
the LPA locus affects AVS risk and Mendelian randomization analyses have supported this 
likely causality { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
A particular challenge in identifying genetic determinants of AVS is that half of patients with 
AVS also have significant CAD { ADDIN EN.CITE { ADDIN EN.CITE.DATA }} and 
therefore care is required in genetic studies of AVS to minimize the possibility that any 
association observed is not simply a proxy for an association with CAD. Based on the common 
co-occurrence and shared key risk factors of the two diseases Helgadottir and colleagues 
recently investigated common CAD associated variants in AVS cases{ ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}. A combined genetic risk score of 71 CAD variants was associated 
with risk of AVS. However, the significant result completely disappeared after adjusting for 
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CAD { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. Therefore, in the current study we 
took specific measures not previously utilized and avoiding any spurious association due to the 
co-occurrence of CAD. Indeed, the LPA locus and rs10455872 specifically have also been 
found to be strongly associated with CAD { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. 
However, the consistent findings across the six comparisons, as well as the external validation 
in five additional cohorts, strongly suggest that there is a specific association of the LPA locus 
with AVS and that our finding as well as those of previous studies where CAD was not always 
accounted for is not due to confounding.  
Our findings in this large study of patients with hemodynamically significant AVS add to the 
growing body of evidence, based on a strong genetic foundation, that Lp(a) is a viable 
therapeutic target for AVS { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}. The finding 
comes at a particularly relevant time as recently several lipid-lowering therapies have been 
developed, including PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors { 
ADDIN EN.CITE 
<EndNote><Cite><Author>Sabatine</Author><Year>2015</Year><RecNum>100</RecNu
m><DisplayText>[23]</DisplayText><record><rec-number>100</rec-number><foreign-
keys><key app="EN" db-id="rppdfdx57tvp2lezwacv2s5rawafxdfe52w0" 
timestamp="1505306610">100</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Sabatine, M. 
S.</author><author>Wasserman, S. M.</author><author>Stein, E. 
A.</author></authors></contributors><titles><title>PCSK9 Inhibitors and Cardiovascular 
Events</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-
title>N Engl J Med</full-title></periodical><pages>774-
5</pages><volume>373</volume><number>8</number><keywords><keyword>Antibodies, 
Monoclonal/*therapeutic use</keyword><keyword>Anticholesteremic Agents/*therapeutic 
use</keyword><keyword>Cardiovascular Diseases/*prevention &amp; 
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control</keyword><keyword>Cholesterol, 
LDL/*blood</keyword><keyword>Female</keyword><keyword>Humans</keyword><key
word>Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic 
use</keyword><keyword>Hypercholesterolemia/*drug 
therapy</keyword><keyword>Male</keyword></keywords><dates><year>2015</year><pu
b-dates><date>Aug 20</date></pub-dates></dates><isbn>1533-4406 
(Electronic)&#xD;0028-4793 (Linking)</isbn><accession-num>26295078</accession-
num><urls><related-
urls><url>https://www.ncbi.nlm.nih.gov/pubmed/26295078</url></related-
urls></urls></record></Cite></EndNote>} and antisense oligonucleotides { ADDIN EN.CITE 
{ ADDIN EN.CITE.DATA }} that lower plasma Lp(a) levels. Indeed, a loss of function 
mutation (R46L) in PCSK9 mimicking the effect of PCSK9 inhibitors have been found to be 
associated with lower Lp(a) level and reduced risk of AVS { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. Modelling of the population impact of Lp(a) lowering has found that Lp(a) 
lowering among the top 20% of the population distribution of Lp(a) could prevent 1 in 7 cases 
of AVS { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}.  
Although, the weaker association of the LPA locus with risk of AVS in patients with CAD was 
not statistically different from that in patients without CAD, there was a consistent pattern 
across all cohorts (Figure 1 and 2) and it is therefore interesting to briefly speculate why this 
may be the case. As discussed earlier, we did not find evidence of a survival effect. It is however 
possible that earlier risk factor management and pharmacological intervention in patients with 
CAD, might have attenuated the subsequent LPA genotype-related risk of developing AVS. 
Although lipid-lowering trials of statins in patients with AVS have not shown a substantial 
reduction in disease progression { ADDIN EN.CITE { ADDIN EN.CITE.DATA }}, this might 
be explained by a too late medical intervention or a too short follow-up time. Furthermore, 
beneficial effects of RAS inhibition in patients with AVS have been shown { ADDIN EN.CITE 
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{ ADDIN EN.CITE.DATA }} and although the data is controversial, RAS blockade may retard 
progression of aortic valve calcification and stenosis { ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }}. Our analysis in the TAVR cohort suggests that especially, in patients 
without CAD and thus less stringent management of risk factors, high Lp(a) levels seem to be 
a factor in AVS progression resulting in symptomatic AVS four years earlier than in patients 
with low Lp(a) levels. This again underlines the therapeutic potential of Lp(a) lowering 
therapies.  
In contrast to the finding with rs10455872, we observed no association of the strongest CAD 
risk allele at 9p21 { ADDIN EN.CITE { ADDIN EN.CITE.DATA }} and even a small 
protective effect in the meta-analysis of the GeneCAST cohorts. However, we could not 
replicate this small effect in five external cohorts, making it unlikely that it is of clinical 
relevance.  
Our study has some limitations which need to be considered. First, we used a candidate 
approach only investigating the association of two risk variants with AVS. The findings, 
however, highlight the potential of genetic studies in this disease, especially when potential 
confounding by CAD is taken into consideration. Second, our study is a cross-sectional analysis 
not providing longitudinal data. Therefore, future studies are warranted testing further 
cardiovascular risk variants and their long-term impact on both AVS development and 
progression. In particular, variants which are associated with blood pressure, cholesterol traits 
and inflammation may help to further clarify the role of these processes in the pathogenesis of 
AVS. Our analysis here demonstrates that the GeneCAST cohorts have the strong potential to 
contribute to such analyses. Finally, our study cohorts were predominantly of Caucasian origin 
and whether the observed associations hold for other ethnic groups remains to be determined.  
In conclusion, our study provides further evidence for a role of variation at the LPA locus in the 
aetiology of AVS which is distinct from the association of this locus with CAD. Especially, in 
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patients without CAD the genetic contribution of the LPA risk allele and subsequent high Lp(a) 
levels result in faster AVS progression.  
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Figure Legends 
 
Figure 1 – Analysis of the LPA and 9p21 loci with risk of AVS in the discovery cohorts 
The (CAD) risk alleles at the LPA locus (rs10455872) and at the 9p21 locus (rs1333049) were 
analysed for their association with risk of aortic valve stenosis (AVS) in three cohorts of the 
GeneCAST (Genetics of Calcific Aortic STenosis) Consortium. Both loci in the three cohorts 
were stratified for CAD status. In addition, a meta-analysis in the stratified groups as well as 
an overall meta-analysis was performed. The CAD risk allele at the LPA locus was concordantly 
associated with increased risk of AVS, whereas the 9p21 CAD risk allele was significantly 
associated with a lower risk of AVS. Odds Ratio; CI, Confidence interval.  
 
Figure 2 – Replication analysis of the LPA and 9p21 loci with risk of AVS 
External validation for the association analysis of the LPA (rs10455872) and the 9p21 
(rs1333049) risk locus in five additional cohorts comprising 7,880 cases and 851,192 controls. 
Again, both loci are stratified for CAD status. Analysis of the LPA risk allele showed similar 
effect estimates, whereas in the replication studies the 9p21 CAD risk allele did not show an 
association with risk of AVS. 
 
Figure 3 – LP(a) levels in patients with symptomatic AVS undergoing TAVR 
 
Age at TAVR due to severe symptomatic AVS stratified by CAD status. Lp(a) levels were 
classified into quartiles from low (1st quartile) to high (4th quartile) Lp(a) serum level.  
 
 
 
 
